Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Charlie Kirk shot dead
  • Nepal protests
  • Russia-Poland tension
  • Israeli strikes in Qatar
  • Larry Ellison
  • Apple event
  • Sunjay Kapur inheritance row
fp-logo
Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • India
  • Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19

Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19

Press Trust of India • June 15, 2020, 12:36:43 IST
Whatsapp Facebook Twitter

HCQ has demonstrated in-vitro activity against SARS-CoV-2 and shown to be clinically beneficial in several small single-centre studies with significant limitations.

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19

The Health Ministry on Saturday recommended the use of antiviral drug in the moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients. It also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating coronavirus-infected patients in moderate stage of the illness. In its revised ‘Clinical Management Protocols for COVID-19’ the ministry dropped the use of azithromycin in combination with hydroxychloroquine (HCQ) in severe cases and requiring ICU management. [caption id=“attachment_8190001” align=“alignnone” width=“1280”]convalescent plasma therapy may be considered for patients with moderate illness with no improvement in condition despite the use of steroids. Representational image. PTI convalescent plasma therapy may be considered for patients with moderate illness with no improvement in condition despite the use of steroids. Representational image. PTI[/caption] Hydroxychloroquine has demonstrated in-vitro activity against SARS-CoV2 and was shown to be clinically beneficial in several small single-centre studies though with significant limitations, it stated. “Nonetheless, several large observational studies with severe methodologic limitations have shown no effect on mortality or other clinically meaningful outcomes. “As such, the evidence base behind its use remains limited as with other drugs and should only be used after shared decision making with the patients while awaiting the results of ongoing studies,” the revised document stated. As is the case with other antivirals, this drug should be used as early in the disease course as possible to achieve any meaningful effects and should be avoided in patients with severe disease, the health ministry said, adding an ECG should ideally be done before prescribing the drug. Under emergency use authorization, remdesivir may be considered for patients in moderate stage requiring oxygen support. It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, the document stated. The drug, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for five days. According to the revised protocols, convalescent plasma therapy may be considered for patients with moderate illness with no improvement in condition despite the use of steroids. The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those into a coronavirus patient to help kickstart the immune system to fight the infection. The recipient should be closely monitored for several hours after transfusion for any adverse events and its use should be avoided in patients with immunoglobulin A deficiency or immunoglobulin allergy. “The dose is variable ranging from 4 to 13 ml/kg – usually 200 ml single dose given slowly over not less than two hours, the revised document stated. The guidelines state that tocilizumab, may be considered in patients with moderate illness with progressively increase in oxygen requirement and in mechanically ventilated patients not improving despite the use of steroids. Long term safety data in COVID 19 remains largely unknown, the guidelines stated. The presence of raised inflammatory markers should be checked before its use and the patient should be carefully monitored after tocilizumab is administered for secondary infections and neutropenia. Active infections and Tuberculosis should be ruled out before use, it stated. For patients with progressive deterioration of oxygenation indicators, rapid worsening on imaging and excessive activation of the body’s inflammatory response, glucocorticoids can be used for a short period of time. Larger dose of glucocorticoids, a class of steroid hormones, will delay the removal of coronavirus due to immunosuppressive effects, the revised document stated. According to the revised clinical management protocols, loss of smell or taste has been added to the list of COVID-19 symptoms. The ministry said that coronavirus-infected patients reporting to various COVID-19 treatment facilities have been reporting symptoms like fever, cough, fatigue, shortness of breath, expectoration, myalgia, rhinorrhea, sore throat and diarrhoea. They have also complained of loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms. The ministry said the use of remdesivir, tocilizumab and convalescent plasma therapy, at present, is based on limited available evidence. As the situation evolves, and when more data become available, the evidence will be accordingly incorporated, and recommendation upgraded, it stated. Further, use of these drugs is subject to limited availability in the country as of now, the document stated. India currently does not manufacture remdesivir Four companies – Hetero, Jubilant Life Sciences, Cipla and Mylan NV – with which the original drugmaker Gilead Sciences Inc have entered into non-exclusive licensing agreements are still awaiting the nod from the DCGI for manufacturing and selling of remdesivir in India. The drug regulator on June 1 had granted US pharma giant Gilead Sciences marketing authorisation for its drug remdesivir for “restricted emergency use” on hospitalised COVID-19 in the country.

Tags
WHO Vaccine Treatment ventilators isolation Pandemic peak cure tocilizumab Plasma coronavirus Coronavirus outbreak coronavirus cases remdesivir COVID 19 convalescent plasma Coronavirus lockdown coronavirus testing hydroxychloroquine Frontline Workers plasma therapy icu beds easing lockdown restrictions death cases increase in coronavirus cases antibody tests
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

At News18 SheShakti 2025 Delhi, women from sports, cinema, and music discussed breaking barriers. Kriti Sanon and Sanya Malhotra focused on equity in cinema, Mira Erda and Ashalata Devi on sports challenges, and Kavita Krishnamurti stressed humility and perseverance for lasting success.

More Impact Shorts

Top Stories

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV